Biotest Pharmaceuticals Corporation ("Biotest Pharmaceuticals") is a US company that researches and manufactures biotherapeutic products with a specialization in immunology and hematology. The company leverages the strong heritage of its global parent company Biotest AG, a German-based global provider of plasma protein therapies, to develop, manufacture and distribute clinical immunology therapeutics for patients with chronic life-threatening conditions, such as Hepatitis B and primary humoral immunodeficiency.
Established in 2007, Biotest Pharmaceuticals owns and manages plasmapheresis centers across the United States. Biotest has recently invested more than $50 million to modernize the U.S. manufacturing operation in Boca Raton, Fla., ensuring that the company continues to support safe and innovative plasma product manufacturing in its state-of-the-art facility.
In March 2014 Biotest Pharmaceuticals employed more than 930 people in the United States.
Important Safety Information for Nabi-HB®
Individuals known to have had an anaphylactic or severe systemic reaction to human globulin should not receive Nabi-HB® [Hepatitis B Immune Globulin (Human)] or any other human immune globulin. Individuals who are deficient in IgA have the potential to develop antibodies against IgA and anaphylactic reactions.
In patients who have severe thrombocytopenia or any coagulation disorder that would contraindicate intramuscular injections, Nabi-HB should be given only if the expected benefits outweigh the potential risks.
Nabi-HB is made from human plasma. Products made from human plasma may carry a risk of transmitting infectious agents (e.g., viruses) and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent.
Nabi-HB [Hepatitis B Immune Globulin (Human)], must be administered only intramuscularly for post-exposure prophylaxis.
Vaccination with live virus vaccines (e.g., MMR) should be deferred until approximately three months after administration of Nabi-HB.
The most common adverse reactions associated with Nabi-HB in clinical trials were erythema and ache at the injection site as well as systemic reactions such as headache, myalgia, malaise, nausea and vomiting. No anaphylactic reactions with Nabi-HB have been reported.
Please see the full Prescribing Information for Nabi-HB [Hepatitis B Immune Globulin (Human)].
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/MedWatch or call 1-800-FDA-1088.